ARTICLE | Company News
ZymoGenetics, Novo Nordisk deal
February 2, 2009 8:00 AM UTC
ZymoGenetics reacquired rights to develop and commercialize IL-21 outside North America. The recombinant IL-21 is in Phase II testing to treat metastatic melanoma and renal cell carcinoma (RCC). ZymoG...